Introduction
Human immunodeficiency virus (HIV) encephalopathy covers a range of HIV-related central nervous system (CNS) dysfunction. The most severe is HIV-associated dementia (HAD), which is the most common cause of dementia in adults under 40.
1 HIV-associated dementia was estimated to affect as many as 30% of patients with advanced AIDS, 2 but has become less common since highly active antiretroviral therapy was introduced. 3 This reduction probably reflects better control of HIV in the periphery, since antiretroviral drugs penetrate the CNS poorly. Before the introduction of highly active antiretroviral therapy, most neuroAIDS patients showed subcortical dementia, with predominant basal ganglia involvement, manifesting as psychomotor slowing, Parkinsonism, behavioral abnormalities and cognitive difficulties. 4 As survival improves, the prevalence of HIV encephalopathy continues to rise, and a less fulminant form of HIV-related neurological dysfunction, minor neurocognitive/motor disorder, is more commonly seen and remains a significant independent risk factor for AIDS mortality. 1, 5 The number of HIV-infected individuals over 50 years of age is rapidly growing, including patients taking highly active antiretroviral therapy. 6 It has been suggested that in 10 years, 50% of AIDS patients in the United States will be over the age of 50. Moreover, it is becoming clear that the brain is an important reservoir for the virus, and neurodegenerative and neuroinflammatory changes may continue despite highly active antiretroviral therapy. 7 Neurons themselves are rarely infected by HIV-1. Neuronal damage is felt to be mainly indirect. HIV-1 infects resident microglia, periventricular macrophages and some astrocytes, 8 leading to increased production of cytokines, such as interleukin-6, interleukin-1b and tumor necrosis factor-a, and chemokines such as monocyte chemoattractant protein-1 (MCP-1). 9 Microglia and macrophages also release HIV-1 proteins, several of which are neurotoxins: envelope (Env) proteins gp120 and gp41, and the nonstructural proteins Tat, Nef, Vpr and Rev.
Soluble gp120 can induce apoptosis in a wide variety of cells including lymphocytes, 10 cardiomyocytes 11 and neurons. 12, 13 HIV gp120 may be directly neurotoxic at high concentrations.
14 Gp120-induced apoptosis has been demonstrated in studies in cortical cell cultures, in rat hippocampal slices and by intracerebral injections in vivo.
15 Gp120 binds neuron cell membrane co-receptors (CCR3, CCR5 and CXCR4) and elicits apoptosis, apparently via G-protein-coupled pathways. 16, 17 Soluble gp120 also increases glial cell release of arachidonate, which impairs neuron and astrocyte reuptake of glutamate, 18 leading to prolonged activation of N-methyl-D-aspartate receptor with consequent disruption of cellular Ca 2+ homeostasis. 19 This process involves generation of superoxide and peroxide species, with resultant oxidative stress, and leads to neuron cell death after mitochondrial permeabilization, cytochrome c release and activation of caspases and endonucleases. 20 We recently reported that exposure to HIV-1 Env gp120 in vitro, or by injection in vivo, induced neuronal apoptosis, which was prevented by prior local transduction with SV(SOD1) and SV(GPx1). 21 Here we describe a study of gp120-mediated apoptosis in the caudateputamens (CP), as well as in vivo protection of CNS neurons by rSV40 delivery of anti-oxidant enzymes SOD1 and GPx1. We compare localized intracerebral inoculation with the more general transduction achieved using intraventricular inoculation and document the ability of the latter to protect neurons from potent localized challenge in the CP with gp120-induced oxidant stress.
Results

Direct injection of gp120 into the CP elicits apoptosis
After injection of different concentrations of gp120 (100, 250 and 500 ng ml
À1
) into the CP, terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) assays were performed from 6 h to 14 days, to detect neuron apoptosis. TUNEL-positive cells were counted in the whole CP, in four different sections for each animal. There were extremely rare TUNELpositive cells when the CP was injected with saline (negative control). At all doses of gp120, TUNEL-positive cells peaked 1 day after the injection ( Figure 1a) , and apoptotic nuclei were confirmed by transmission electron microscopy (TEM) (Figure 1b) . The time course of apoptosis is shown in Figure 2 . As a positive control for our TUNEL assay, we injected kainic acid, a drug known to induce apoptosis in hippocampal neurons, intraperitoneally (i.p.), and assayed neurons of the dentate gyrus (DG) by TUNEL.
Gp120-induced apoptotic cells are mainly neurons
Sections from the striatum obtained 1 day after gp120 injection were double stained for TUNEL and NeuroTrace (NT), a marker of neurons similar to the Nissl staining. Nuclei were stained by 4 0 ,6-diamidino-2-phenylindole. After injection of 250 or 500 ng gp120, numerous TUNEL-positive cells were seen, the vast majority of which were also immunopositive for Nissl (Figure 3a) or neuN (Figure 3b ) identifying them as neurons. By contrast, occasional TUNEL-positive cells were also CD68-positive, and so were consistent with microglia ( Figure 3c ). rSV40-delivered SOD1 and GPx1 in the CP reduces apoptotic cells after gp120 injection SV(SOD1), SV(GPx1) or SV(BUGT), the latter being a control rSV40 vector, was administered on one side of the brain in the CP and transgene expression was studied at different times thereafter. To assess the level of neuroprotection from gp120-induced apoptosis provided by rSV40-delivery of SOD1 and GPx1 into the striatum, we injected 500 ng gp120 into the CP at different time points after transduction and measured apoptosis by TUNEL assay. At all time points, fewer apoptotic cells were seen in brains whose CP have been previously injected with SV(SOD1) and SV(GPx1), compared to CP injected with SV(BUGT) (Figure 4d ). Compared to injection of SV(BUGT), morphometric analysis showed significantly fewer TUNEL-positive cells after injection of SV(SOD1) or SV(GPx1), 4 weeks (Po0.01 and Po0.01, respectively), 8 weeks (Po0.01 and Po0.01, respectively) and 24 weeks (Po0.01 and Po0.01, respectively) after the injection (Figure 4e ).
Intraventricular vector administration of SV(SOD1) and SV(GPx1) provides widespread transgene expression in the brain and is effective in protecting neurons from local challenge with gp120 SV(SOD1) and SV(GPx1) were injected in the right lateral ventricle (LV) and transgene expression was studied 4
Gene transfer to protect neurons from gp120-induced apoptosis J-P Louboutin et al and 8 weeks later. Increased expression of SOD1 and GPx1, respectively, was shown on western analysis performed on frontal cortex 1 and 2 months after vector injection ( Figure 5a ). There was no detectable expression of SOD1 and GPx1 after injection of SV(BUGT) in the LV. Further, increased expression of GPx1 was not detected in sections of brains injected with SV(SOD1), and expression of SOD1 was also not detected in brains injected with SV(GPx1) (data not shown).
Four and 8 weeks after injection of SV(SOD1), SV(GPx1) or SV(BUGT) into the LV, we injected the CP with 500 ng gp120 and apoptotic cells were enumerated by TUNEL assay 1 day after gp120 challenge. Four weeks after vector injection, brains injected with SV(SOD1) showed fewer apoptotic cells (Po0.01), but brains injected with SV(GPx1) in the LV did not. However, 8 weeks after LV injection, both SV(SOD1) (Po0.01) and SV(GPx1) (Po0.01) protected neurons from apoptosis induced by intracaudate injection of gp120 (illustrated, Figure 5b ; quantitation, Figure 5c ).
Improving gene transfer efficiency and increasing the therapeutic effectiveness of LV injection by prior systemic administration of mannitol
We then studied if rSV40 gene delivery by SV(GPx1) or SV(SOD1) injection into the LV might be facilitated by i.p. injection of mannitol 30 min before the LV injection. Preceding intraventricular inoculation of the rSV40s by i.p. mannitol led to far greater expression of SOD1 in the frontal cortex as demonstrated by western blot analysis Figure 1 HIV-1 gp120 induces apoptosis in CNS cells in vivo: dose response and time course. Apoptosis was assessed by TUNEL assay at different time points, after injection of different concentrations of gp120 into the rat CP. Negative control rats received saline in the CP, while the DG was examined in positive control rats, which received i.p. injection of kainic acid, a drug known for inducing apoptosis in hippocampus (a). Apoptotic nuclei were demonstrated by TEM 1 day after injection of 500 ng gp120 in the CP, compared to normal nuclei observed in the absence of injection of gp120 (b). CNS, central nervous system; CP, caudate-putamen; DG, dentate gyrus; HIV-1, human immunodeficiency virus-1; i.p., intraperitoneal; TEM, transmission electron microscopy; TUNEL, terminal deoxynucleotidyl transferasemediated biotinylated UTP nick end labeling. Gene transfer to protect neurons from gp120-induced apoptosis J-P Louboutin et al ( Figure 6a ), and increased the numbers of neurons that were immunopositive for SOD1 (data not shown).
Frontal cortex sections from rats receiving the control vector (SV(BUGT)) did not demonstrate SOD1 expression. Similar results were obtained with SV(GPx1) (Figure 6b ). Four weeks after the administration of mannitol i.p. followed by either SV(GPx1), SV(SOD1) or SV(BUGT) in the LV, we injected the CP with 500 ng gp120. Neurotoxicity was assessed by TUNEL 1 day after the intracaudate gp120 challenge. A significant decrease in the number of TUNEL-positive cells was noted when mannitol was administered i.p. before injecting SV(SOD1) (Po0.01) and SV(GPx1) (Po0.01) into the LV (illustrated, Figure 6b ; quantitation, Figure 6c ). Administration of mannitol before injection of the control vector, SV(BUGT), into the LV did not change significantly the number of apoptotic cells (Figures 6b and c) .
Discussion
Abnormalities in oxidative metabolism have been reported in many nervous system diseases. These include Gene transfer to protect neurons from gp120-induced apoptosis J-P Louboutin et al neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis and cerebellar degeneration), [22] [23] [24] [25] [26] vascular diseases (ischemia-reperfusion) 27 or toxic reactions (chronic alchoholism), 28 as well as aging. 29 Oxidative stress can play a role in HIV-1-associated dementia in several ways. Circulating toxins in the CSF, derived from HIV-1-infected cells, may damage mitochondria, leading to release of cytochrome c and then to a cascade of events leading to apoptosis. 30, 31 HIV-1 gp120 and Tat can cause free radical production, possibly as part of the signal-transduction pathways they activate. 1, 32 It has been previously shown that HIV-1 gp120 can cause lipid peroxidation and production of hydroxynonenal esters, 33 which can mediate oxidative stressinduced apoptosis of cultured neurons 34 and can damage neurons and cause cognitive dysfunction in vivo.
35
Hydroxynonenal ester-positive neurons have been found in brains of patients with HIV-1 encephalitis. 31 A potential therapeutic strategy for the treatment of neuroAIDS might be to limit oxidative stress-related neurotoxicity. Gene transfer of antioxidant enzymes has been achieved in a gene therapy perspective in numerous models of neurological disorders by using diverse viral vectors: lentiviruses, 36 herpes simplex 37 and adenovirus. 38 However, adenovirus-mediated gene transfer to the brain is limited by innate immunity and acquired immune responses against the virus, and against foreign transgenes as well, that limit the duration of transient gene expression. 39 Development of gutted vectors, manipulation of host immune responses and use of less immunogenic transgenes may circumvent these limitations, but success to date has been limited. 40 Vectors derived from adeno-associated viruses (AAV) may deliver long-term transgene expression in the brain, with Figure 4 rSV40 delivery of SOD1 and GPx1 into the CP results in transgene expression in neurons and largely protects neurons from gp120-induced apoptosis. Rats were given SV(SOD1), SV(GPx1) or (negative rSV40 control vector) SV(BUGT) into their CP by stereotaxic injection. CP received 5 ml of rSV(SOD1) or SV(GPx1) viral vector, which contains approximately 10 7 particles, as determined by Q-PCR. Transgene expression was studied at different time points after the injection by western analysis and immunostaining. (a) Western blotting done 1 month after vector injection tested expression of SOD1 and GPx1 on the side injected with SV(SOD1) (SV(SOD1) inj CP) and SV(GPx1) (SV(GPx1) inj CP) respectively. GAPDH was used as loading control. (b) At 4 and 24 weeks after injection of SV(SOD1) into the CP, SOD1 expression was assessed by immunostaining. Sections were co-immunostained for NeuroTrace. Injection of the CP with SV(BUGT), and the analysis of the uninjected side, were used as negative controls. (c) Higher magnification of co-immunostaining for SOD1 and neuN, another neuronal marker, 4 weeks after injection of SV(SOD1) into the CP. (d) To assess the level of neuroprotection against gp120-induced apoptosis provided by rSV40-delivered SOD1 and GPx1 in the striatum, we injected 500 ng gp120 in the CP at different times after prior injection of the antioxidant-carrying vector. Apoptosis was studied by TUNEL assay, compared to brains injected with the control rSV40 vector, SV(BUGT). (e) Quantitation of apoptotic cells and protection from apoptosis by SV(SOD1) and SV(GPx1). One day after injection of 500 ng gp120, we performed morphometry to quantitate the protective effect of rSV40 delivery of the two antioxidant genes on Env-induced apoptosis. Env, envelope; CP, caudate-putamen; GAPDH, glyceraldehyde-3-phosphate-dehydrogenase; TUNEL, terminal deoxynucleotidyl transferasemediated biotinylated UTP nick end labeling; Q-PCR, quantitative PCR.
Gene transfer to protect neurons from gp120-induced apoptosis J-P Louboutin et al little, if any, inflammatory response after intracerebral injection. 41 Cell tropism and transduction efficiency of AAVs can be modified by using different AAV serotypes. [42] [43] [44] However, transgene size is limited to below 4 kb. Gene transfer to rodent and primate CNS in vivo has been demonstrated with lentiviral vectors derived from HIV and other lentiviruses, delivering both marker and potentially therapeutic genes to neurons. 45, 46 We used rSV40 vectors here to deliver therapeutic gene into the brain because they transduce cells in G 0 with high efficiency and integrate into their genomes to provide permanent transgene expression. We observed efficient, sustained gene transfer to rat brain: injection into the CP resulted in many cells expressing the transgene, and transgene expression continued undiminished at least 6 months after intracaudate injection. This is consistent with other studies in which rSV40 transduction of several organs has proven long lived. [47] [48] [49] The present study demonstrates that a single injection of SV40-derived vectors into the striatum transduces brain cells. They can also carry somewhat larger transgenes (5 kb) than does AAV. Unlike adenoviruses, rSV40s do not elicit inflammatory responses. Interestingly, the estimated number of cells that expressed the rSV40-delivered transgene (400 000-500 000) is similar to figures obtained using AAV2/5, perhaps the best rAAV so far for transducing the striatum. 44 Moreover, the number of transgenepositive cells was stable throughout the 6-month study period after injection, while transgene expression reportedly declines over time with adenovirus 39 and rAAV vectors. 50 In a previous study, rSV40 vectors were effective in transducing both neurons and microglia, upon intracerebral inoculation. 51 Transduction of cultured NT2-derived neurons by rSV40s has been reported previously, 52 and effective rSV40-mediated gene transfer to microglia (which are reported as targets for gene delivery) has been shown as well in culture. 53 Preliminary studies also found evidence of gene transfer by intracerebral injection of SV-based vectors into the basal ganglia.
54 rSV40s did not transduce astrocytes appreciably in vivo in the current studies. Similar results have been obtained using cultured astrocytes (L Agrawal et al., unpublished).
Intraventricular administration of rSV40 vectors resulted in transduction of neurons in a preliminary study, but when applying substantially higher doses than were used here. 52 In the present study, sustained transgene expression was achieved after injecting rSV40 vectors in the LV. Levels of expression attained were functionally significant: they protected from neuron apoptosis caused by localized gp120 injection into the CP. Thus, intraventricular rSV40 injection provides sufficiently generalized gene transfer to protect from localized challenge at a distance from the site of vector inoculation. Better results were obtained with SV(GPx1) at 2 months than at 1 month after injection into the LV, perhaps reflecting time needed to accumulate the transgene product. Neuroprotection with SV(SOD1), however, was similar 1 and 2 months after vector injection. Although not all regions of the brain were tested with gp120 challenge, these results suggest that intraventricular administration of SV40-derived vectors may hold promise for diffuse gene delivery to the CNS.
Systemic mannitol-induced hyperosmolarity improved transgene expression after injection of SV(SOD1) and SV(GPx1) in the LV, most likely by increasing the number of cells exposed to the administered vector. Few studies have reported the effects on CNS transgene expression of prior injection of mannitol; some were based on injection of AAVs into the striatum or cisterna magna, 43 or of adenovirus into the LV. 55 However, there is little information on the therapeutic effects of vectors injected that way. Combining injection of rAAV 56 or adenovirus 57 with mannitol enhances gene expression in the rat brain, but systemic mannitol-induced hyperosmolarity provides greater rAAV2-mediated striatal transduction than does local co-infusion. 58 Mannitol is reported to enhance transgene expression by opening the blood-brain barrier. 59 
Figure 5
Protection provided by intraventricular injection of SV(SOD1) and SV(GPx1) from gp120-induced apoptosis when gp120 is injected in the CP. SV(SOD1) and SV(GPx1) were administered in the right LV. (a) Expression of SOD1 and GPx1 was studied 4 and 8 weeks after the injection. Expression of SOD1 and GPx1 on the side injected with SV(SOD1) and SV(GPx1) was assessed by western blotting 1 and 2 months, respectively, after vector injection. (b) At 4 and 8 weeks after injection of SV(SOD1), SV(GPx1) or SV(BUGT) into the LV, we injected the CP with 500 ng gp120 and apoptotic cells were numbered after TUNEL assay. (c) Quantitation of protection afforded by intraventricular gene delivery followed by localized challenge with gp120. Morphometric analysis of CP sections in rats receiving test or control vectors via lateral ventricle 4 or 8 weeks prior to challenge with 500 ng HIV-1 gp120. CP, caudate-putamen; HIV-1, human immunodeficiency virus; LV, lateral ventricle; TUNEL, terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling.
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It may be possible to increase the number of transgenepositive cells further by using multiple inoculations. This approach increases the number of rSV40-transduced cells in studies in vivo targeting other organs [47] [48] [49] and the unique ability of rSV40 vectors to avoid eliciting neutralizing antibodies may provide increased transduction to the CNS without loss of gene transfer efficacy due to vector-specific immune responses. 60 Therefore, either local or diffuse delivery of antioxidant enzymes SOD1 and GPx1 using rSV40 vectors provides substantial neuroprotection from the oxidative stress and neuronal death associated with HIV-1 gp120. Interesting data could also be provided by behavioral assays focused on the basal ganglia (rotational behavior, 50 behavioral testing of sensitivity to psychostimulants 61 ). However, HIV encephalopathy involves a lifetime CNS infection that may serve as a reservoir for the virus. This time framework could be a challenge for any therapeutic approach. Even as SV40 vectors integrate in the genome, the consequences of long-term delivery of antioxidant molecules are unknown. We are currently investigating conditional expression of these antioxidant Gene transfer to protect neurons from gp120-induced apoptosis J-P Louboutin et al genes, to test limiting expression to conditions of oxidative stress. Taken together, the present findings have potential implications for therapies of other neurological diseases in which protein, lipid and DNA oxidation may play important roles.
Materials and methods
Animals
Female Sprague-Dawley rats (200-250 g) were purchased from Charles River Laboratories (Wilmington, MA, USA). Protocols for injecting and euthanizing animals were approved by the Thomas Jefferson University IACUC, and are consistent with AAALAC standards.
Antibodies
Different primary antibodies were used: mouse antiNeuN (1:100) (Chemicon International, Temecula, CA, USA), mouse anti-rat CD68/ED1 (1:50) (Serotec, Oxford, UK), rabbit anti-human SOD1 (1:100), mouse anti-GPX1 (1:100) (Stressgen, Victoria, BC, Canada). Secondary antibodies were used at 1:100 dilution: fluorescein isothiocyanate-and tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-mouse, TRITC-conjugated goat anti-rabbit, fluorescein isothiocyanate-conjugated sheep anti-rabbit (Sigma, Saint-Louis, MO, USA), fluorescein isothiocyanate-and TRITC-conjugated donkey anti-mouse antibodies (Jackson ImmunoResearch Laboratories Inc., WestGrove, PA, USA).
Vector production
The general principles for making recombinant, Tagdeleted, replication-defective SV40 viral vectors have been previously reported.
62 SOD1 and GPx1 transgenes were subcloned into pT7 [RSVLTR] , in which transgene expression is controlled by the Rous sarcoma virus longterminal repeat (RSV-LTR) as a promoter. The cloned rSV40 genome was excised from its carrier plasmid, gelpurified and re-circularized, then transfected into COS-7 cells. These cells supply in trans large T-antigen (Tag) and SV40 capsid proteins, which are needed to produce recombinant replication-defective SV40 viral vectors. 63 Crude virus stocks were prepared as cell lysates, then band-purified by discontinuous sucrose density gradient ultracentrifugation and titered by quantitative PCR (Q-PCR; Stratagene Inc.).
64,65 SV(BUGT), which was used here as a negative control vector, has been reported. 48 Experimental design Apoptosis study. To test gp120-induced apoptosis, different doses of gp120 (100, 250 and 500 ng ml Transgene expression study. SV(SOD1) and SV (GPx1) were injected in the CP of 24 rats, whose brains were harvested 4, 8 and 24 weeks after injection, 4 rats at each time point for each vector. Fifty microliters of SV(SOD1) and SV(GPx1) was injected in the LV of eight rats and the brains of these animals were examined 4 (n ¼ 4) and 8 weeks (n ¼ 4) after injection.
For the mannitol study, 3 ml of sterile 25% mannitol in 0.9% saline/100 g body weight was injected i.p. 30 min before injection of 50 ml of SV(SOD1) and SV(GPx1) in the LV in eight rats. Their brains were examined 4 and 8 weeks after vector injection (n ¼ 4 for each time point). In all cases, controls received saline or SV(BUGT) instead of SV(SOD1) and SV(GPx1) in the CP or the LV.
Challenge with gp120. To study neuroprotection by rSV40-mediated overexpression of SOD1 and GPx1 from gp120-related apoptosis, the CP of rats in which SV(SOD1) and SV(GPx1) were administered either directly in the CP or in the LV was injected with 500 ng gp120. Brains were injected with gp120: 4, 8 and 24 weeks after vector injection into the CP; 4 and 8 weeks after injection into the LV; 4 weeks after injection into the LV after i.p. administration of mannitol 30 min before. In all cases, brains were harvested 1 day after injection of 500 ng gp120 into the CP, and studied for apoptosis by TUNEL assay (n between 3 and 5). In all cases, controls received SV(BUGT) instead of SV(SOD1) and SV(GPx1) in the CP or the LV.
In vivo transduction and injection of gp120
Rats were anesthetized with isofluorane UPS (BaxterHealthcare Corp., Deerfield, IL, USA) (1.0 U isofluorane per 1.5 l O 2 per minute) and placed in a stereotaxic apparatus (Stoelting Corp., Wood Dale, IL, USA) for cranial surgery. Body temperature was maintained at 37 1C by using a feedback-controlled heater (Harvard Apparatus, Boston, MA, USA). Glass micropipettes (1.2 mm outer diameter; World Precisions Instruments Inc., Sarasota, FL, USA) with tip diameters of 15 mm were backfilled with 5 ml of rSV(SOD1) or SV(GPx1) viral vector, which contains approximately 10 7 particles. The vector-filled micropipettes were placed in the LV or CP using coordinates obtained from the rat brain atlas of Paxinos and Watson. 66 For injection into the CP, a burr hole was placed +0.48 mm anterior to bregma and À3.0 mm lateral to the sagittal suture. Once centered, the micropipette was placed 6.0 mm ventral from the top of the brain. The same coordinates were used for injection of gp120 into the CP. For LV injection, a burr hole was placed À0.26 mm posterior to bregma and À1.0 mm lateral to the sagittal suture. Once centered, the micropipette was placed À3.4 mm ventral from the top of the brain. The vector was given by a Picospritzer II (General Valve Corp., Fairfield, NJ, USA) pulse of compressed N 2 of duration 10 ms at 20 psi until the fluid was completely ejected from the pipette. Following surgery, animals were housed individually with free access to water and food.
Gene transfer to protect neurons from gp120-induced apoptosis J-P Louboutin et al After a variable survival period, rats were anesthetized via i.p. injection of sodium pentobarbital (Abbott Laboratories, North Chicago, IL, USA) at 60 mg kg À1 and perfused transcardially through the ascending aorta with 10 ml or heparinized saline followed by ice-cold 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA, USA) in 0.1 M phosphate buffer (pH 7.4). Immediately following perfusion-fixation, the rat brains were dissected out, placed in 4% paraformaldehyde for 24 h, then in a 30% sucrose solution for 24 h and frozen in methyl butane cooled in liquid nitrogen. The samples were cut on a cryostat (10 mm sections).
Immunocytochemistry
For immunofluorescence, coronal cryostat sections (10 mm thick) were processed for indirect immunofluorescence. Blocking was performed by incubating for 60 min with 10% goat, or 10% donkey, serum in phosphate-buffered saline (PBS) (pH 7.4). Then, sections were incubated with antibodies diluted according to the manufacturer's recommendations: 1 h with primary antibody, then 1 h with secondary antibody diluted 1/100, all at room temperature. Double immunofluorescence was performed as described previously. 67 All incubations were followed by extensive washing with PBS. To stain nuclei, we used mounting medium containing 4 0 ,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). Specimens were finally examined under a Leica DMRBE microscope (Leica Microsystems, Wetzlar, Germany). Negative controls consisted of preincubation with PBS and 0.1% bovine serum albumin, substitution of non-immune isotype-matched control antibody for primary antibody, and/or omission of the primary antibody.
Staining of neurons using NT
After rehydration in 0.1 M PBS (pH 7.2) sections were treated with PBS plus 0.1% Triton X-100 for 10 min, washed twice for 5 min in PBS and then stained by NT (Molecular Probes Inc., Eugene, OR, USA) (1:100), a fluorescent Nissl stain, for 20 min at room temperature. Sections were washed in PBS plus 0.1% Triton X-100, then Â 2 with PBS and were left undisturbed for 2 h at room temperature in PBS before being counterstained with 4 0 ,6-diamidino-2-phenylindole. Combination NT+ antibody staining was performed using primary and secondary antibodies staining first (see above), followed by staining with the NT fluorescent Nissl stain. Experiments were repeated three times and were carried out the same day for the different sections considered.
General morphology
Microscopic morphology of the brain was assessed by NR staining of cryostat sections.
Transmission electron microscopy
Adult female Sprague-Dawley rats were used for this study, with or without the injection of gp120 in the CP. One day after the injection of gp120, the rats were deeply anesthetized with sodium pentobarbital (60 mg kg À1 ) and perfused transcardially through the ascending aorta with (1) 10 ml of heparinized saline, (2) 50 ml of 3.75% acrolein (Electron Microscopy Sciences), and 200 ml of 2% formaldehyde in 0.1 M phosphate buffer (PB) (pH 7.4). Immediately after perfusion fixation, brains were removed, sectioned coronally and postfixed in the same fixative overnight at 4 1C.
Alternate 40-mm-thick sections through the CP were processed for electron microscopy. Sections containing the CP were placed for 30 min in 1% sodium borohydride in 0.1 M PB and collected into 0.1 M PB to remove reactive aldehydes. Then sections were rinsed extensively in 0.1 M PB. Subsequently, sections were rinsed three times with 0.1 M Tris-buffered saline, followed by rinses with 0.1 M PB and 0.01 PBS (pH 7.4). Sections were then incubated in 2% glutaraldehyde (Electron Microscopy Sciences) in 0.01 M PBS for 10 min followed by washes in 0.01 M PBS and 0.2 M sodium citrate buffer (pH 7.4). Following washes, tissues were rinsed in 0.2 M citrate buffer and 0.1 M PB, and incubated in 2% osmium tetroxide (Electron Microscopy Sciences) in 0.1 M PB for 1 h, washed in 0.1 M PB, dehydrated in an ascending series of ethanol followed by propylene oxide and flat embedded in Epon 812 (Electron Microscopy Sciences). Thin sections of approximately 50-100 nm thickness were cut with a diamond knife (Diatome-US, Fort Washington, PA, USA) using a Leica Ultracut (Leica Microsystems). Sections were collected on copper mesh grids, examined with an electron microscope (Morgagni, Fei Company, Hillsboro, OR, USA) and digital images were captured using the AMT advantage HR/HR-B CCD camera system (Advance Microscopy Techniques Corp., Danvers, MA, USA). Figures were assembled and adjusted for brightness and contrast in Adobe Photoshop.
Morphometry
Transduction was assessed for each injected brain (LV and CP injections) by serial cryo-sectioning of the whole brain (10 mm thick coronal sections), each slide being numbered, then by immunostaining of every fifth section for FLAG or SOD1 (that is, at 50-mm intervals, spanning at least 3 mm of tissue rostral and 3 mm caudal to the injection site). This step determined the most anterior and posterior extent of the transduced area. Between 100 and 120 sections were immunostained for each rat. The total number (and not the number in random areas) of FLAG-or SOD1-positive cells in one hemisphere for every fifth section was counted and summed. The final number presented was an average of the results measured in the different sections examined. The total number of positive cells in a brain could be estimated by 'multiplying' the cell counts by the length of the transduced area, assuming that the number of positive cells in the sections spanned between the first and fifth one for example will be close to the one measured on these first and fifth sections. This procedure already described for assessment of number of transgenepositive cells in the brain allows quantitative and relative comparisons among different time points, although it does not reflect the total number of transduced cells in vivo. 50, 51 However, if these calculations of cell counts do not conform to unbiased stereological method, they have been realized on 10 mm thick sections and the total number of positive cells has been counted in each section, while stereological methods are usually applied to 40-50 mm thick sections and analyze random fields of the sections. Moreover, we used our current method for enumerating total neurons in the rat normal striatum by immunocytochemistry (using anti-NeuN antibodies) and staining of neurons by NT. Preliminary results showed a total number of neurons close to the one measured using the optical fractionator method (data not shown).
The longitudinal distribution of the transgene away from the injection site was assessed as the distance between the most distant sections anterior and posterior to the injection site demonstrating transgene expression.
Western analysis
For in vivo protein analysis, brain sections were homogenized in buffer containing protease inhibitors and DNase. Lysates were prepared as reported previously. 21 Total protein was estimated using the bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL, USA). Total cell proteins (100 mg) were loaded in each well, then transferred to Immobilon-P polyvinylidine difluoride membrane (Millipore Inc., Billarica, MA, USA). Equal lane loading was assessed using anti-glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) antibody (1:5000). The blot was realized according to the manufacturer's instructions (Roche). Anti-SOD1 antibody was used at dilutions of 1:500 and anti-rabbit horseradish peroxidase was used at a dilution of 1:5000 before the addition of chemiluminescence substrate (Roche).
Statistical analysis
Comparison of medians between two groups was achieved by using the Mann-Whitney test (with a two-tailed P-value). Comparison of medians between more than two groups was done by using the Kruskall-Wallis test. The difference between the groups was considered significant when Po0.05.
